Key facts
- It has raised $4.5M; the latest was Later Stage VC ($1.5M) in Aug 2024.
- Notable investors include Investissement Quebec, Alexandre Grenier, SiliCycle.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Pharma in silica
- ·The full record, as it builds
Funding rounds
No funding rounds for Pharma in silica are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pharma in silica
Operator of a pharmaceutical company intended to develop tolerable, effective and affordable chemotherapy for solid cancers. The company develops nano-sized silica spheres to bring more anticancer drug into the tumor microenvironment, enabling healthcare professionals to increase the efficacy and reduce the toxicity of paclitaxel, a cytotoxic molecule used daily to treat several cancers.
- Sector
- Healthcare
- HQ
- Quebec, Canada
- Founded
- 2019
- Employees
- 6
- Website
- pharma-insilica.com/
- Ownership
- Privately Held (backing)
Pharma in silica doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pharma in silica shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pharma in silica in its N-PORT filings yet. We sweep new filings monthly.